Abstract
Cisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It remains an important and effective therapy in many forms of cancer today. Cisplatin mediates its tumorcidal effects via a number of different cytotoxic mechanisms. Although it is best known for DNA damage, cisplatin also causes cytoplasmic organelle dysfunction particularly with the endoplasmic reticulum and mitochondria. It also activates apoptotic pathways and inflicts cellular damage via oxidative stress and inflammation. One of its dose limiting toxicities is its effects on the kidney. This includes acute kidney injury as well as tubular injury resulting in electrolyte wasting. Extensive research has found that cisplatin entry into a cell is facilitated by a number of cellular transporters including human copper transport protein 1 (Ctr1) and the organic cation transporter 2 (OCT2) which are expressed on renal tubular cells. The interactions between the mechanisms of cytotoxicity and cellular transport play an important role in the nephrotoxicity. Better understanding of these interactions could one day help devise better renoprotection that would not reduce its anti-tumor effects.
Similar content being viewed by others
References
Prestayko AW, Crooke ST, Carter SK, University of Alabama in Birmingham (1980) Comprehensive Cancer Center., Bristol Laboratories.: Cisplatin, current status and new developments. Academic Press, New York
Liira J, Verbeek JH, Costa G, Driscoll TR, Sallinen M, Isotalo LK, Ruotsalainen JH (2014) Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database Syst Rev 2014(8):CD009776
Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3(1):1351–1371
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007
Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300(1):142–148
Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14(1):1–10
Cozzaglio L, Doci R, Colella G, Zunino F, Casciarri G, Gennari L (1990) A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 76(6):590–594
Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70(1–2):89–101
Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16(1):16–39
Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070–3074
Hanigan MH, Gallagher BC, Townsend DM, Gabarra V (1999) Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20(4):553–559
Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14(7):2101–2112
Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22(5):441–445
Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G (2004) High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 114(9):1660–1667
Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F, Gogioso L (1996) Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Toxicol Appl Pharmacol 140(2):370–377
Viale M, Vannozzi MO, Pastrone I, Mariggio MA, Zicca A, Cadoni A, Cafaggi S, Tolino G, Lunardi G, Civalleri D et al (2000) Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? J Pharmacol Exp Ther 293(3):829–836
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490–2518
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307–320
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467–2498
Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39(1):43–50
Mandic A, Hansson J, Linder S, Shoshan MC (2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278(11):9100–9106
Hirama M, Isonishi S, Yasuda M, Ishikawa H (2006) Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep 16(5):997–1002
Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H, Tostivint I, Deray G (2005) [Anticancer drug-induced nephrotoxicity]. Nephrol Ther 1(2):101–114
Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J, Price P, Li S (2002) Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 62(4):1208–1218
Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D (2004) PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286(3):F572-580.
Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M (2005) Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol 289(6):C1466–C1475
Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z (2008) Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74(5):631–640
Fraser M, Bai T, Tsang BK (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122(3):534–546
Chirino YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3):223–242
Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289(1):F166–174
Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z (2007) Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73(9):1499–1510
Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 40(11):1713–1723
Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, Kohn N, Metz CN: Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am J Physiol Renal Physiol 2015, 309(1):F35–47
Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J (2010) The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 6(4):224–235
Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8(4):279–289
Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB (2008) TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19(5):923–932
Tadagavadi RK, Reeves WB (2010) Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. J Immunol 185(8):4904–4911
Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 65(2):490–499
Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W (2009) Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24(10):3012–3020
Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Investig 110(6):835–842
Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99(22):14298–14302
Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296(3):F505–511
Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495–535
Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17(6):574–583
Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW (1984) Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 44(8):3632–3635
Klein J, Bentur Y, Cheung D, Moselhy G, Koren G (1991) Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Investig Med 14(5):388–394
Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67(6):1518–1524
Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243–266
Koepsell H, Schmitt BM, Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36–90
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86(4):396–402
Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH et al (2010) Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176(3):1169–1180
Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167(6):1477–1484
Yonezawa A, Inui K (2011) Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81(5):563–568
Urakami Y, Akazawa M, Saito H, Okuda M, Inui K (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13(7):1703–1710
Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60(11):2823–2828
Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32(7):685–690
Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83(6):866–869
Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307–314
Maxwell MH, Kleeman CR, Narins RG (1994) Maxwell & Kleeman’s clinical disorders of fluid and electrolyte metabolism, 5th edn. McGraw-Hill, Health Professions Division, New York
Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90(6):929–931
Sutton RA, Walker VR, Halabe A, Swenerton K, Coppin CM (1991) Chronic hypomagnesemia caused by cisplatin: effect of calcitriol. J Lab Clin Med 117(1):40–43
Goldstein RS, Mayor GH, Rosenbaum RW, Hook JB, Santiago JV, Bond JT (1982) Glucose intolerance following cis-platinum treatment in rats. Toxicology 24(3–4):273–280
Kim YK, Byun HS, Kim YH, Woo JS, Lee SH (1995) Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 130(1):19–26
Wangila GW, Nagothu KK, Steward R, 3rd, Bhatt R, Iyere PA, Willingham WM, Sorenson JR, Shah SV, Portilla D (2006) Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutylsalicylate)4(ethanol)4]. Toxicol In Vitro 20(8):1300–1312
Swainson CP, Colls BM, Fitzharris BM (1985) Cis-platinum and distal renal tubule toxicity. NZ Med J 98(779):375–378
Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C (1981) Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241(2):F175–185
Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A (1989) Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol 9(1):59–65
Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101(1):41–44
Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8(3):164–169
Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, Ostergaard LF, Christensen S, Daugaard G, Jonassen TE (2005) Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56(5):535–542
Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, Safirstein RL, Beger RD (2006) Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69(12):2194–2204
Kim SW, Lee JU, Nah MY, Kang DG, Ahn KY, Lee HS, Choi KC (2001) Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 12(5):875–882
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124
Goldstein RS, Mayor GH, Gingerich RL, Hook JB, Rosenbaum RW, Bond JT (1983) The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol 69(3):432–441
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40(4):293–308
Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304–309
Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77(10):1677–1682
Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu S, Yavuz I, Yenicesu M, Ozet A et al (2002) Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 17(11):1931–1935
Tanaka H, Ishikawa E, Teshima S, Shimizu E (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14(2):247–257
Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32(5):577–590
Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50(2):147–158
Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, van den Heuvel-Eibrink MM (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol CJASN 8(6):922–929
Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW: Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2013(10):CD008944
Li S, Gokden N, Okusa MD, Bhatt R, Portilla D: Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005, 289(2):F469–480
Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S et al (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60(6):2118–2128
Rani N, Bharti S, Tomar A, Dinda AK, Arya DS, Bhatia J (2016) Inhibition of PARP activation by enalapril is crucial for its renoprotective effect in cisplatin-induced nephrotoxicity in rats. Free Radic Res 50(11):1226–1236
Price PM, Safirstein RL, Megyesi J: Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol 2004, 286(2):F378–384
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflict of interest
We do not have any financial or non-financial potential conflicts of interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Rights and permissions
About this article
Cite this article
Manohar, S., Leung, N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol 31, 15–25 (2018). https://doi.org/10.1007/s40620-017-0392-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-017-0392-z